Legal status
In the United States, it is classified as a Schedule V controlled substance by federal law, and is available only for a medical purpose. References
External links
"Atropine sulfate mixture with diphenoxylate hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
Congenital dermal sinus may form at any point along the midline of the neuraxis, however, the majority form in the lumbar and lumbosacral region (41% and 35% of cases respectively). Diagnosis
Congenital dermal sinus is often diagnosed in infants and children. Early diagnosis is important in congenital dermal sinus, so that treatment can be provided early, to prevent progression of associated complications. Clinical features
There three key hallmarks of congenital dermal sinus: cutaneous abnormalities, infection, and neurological deficits. Cutaneous abnormalities
Congenital dermal sinus is a tract from the surface layer of the skin, through the deeper tissues into the cranial or spinal cavity. The skin findings of this tract can include:

Pit along neuraxis
Flat capillary hemangioma
Hypertrichosis
Skin tag
Abnormal pigmentation
Subcutaneous lipoma
Signs of local infection

Infection
The stratified squamous epithelium of the congenital dermal sinus tract can extend to the spinal fascia of the dura mater or all the way to the spinal cord. Thus, the congenital dermal sinus forms a point of entry for infection, this can allow for the formation of an abscess, especially among children. Infection can then travel up the spinal cord to result in meningitis, which can be fatal if left untreated. Neurological deficit
Congenital dermal sinus is often also associated with spinal fluid drainage, intradural cysts and spinal cord tethering; conveying neurological deficit. Neurological deficit can occur due to spinal cord compression from intradural dermoid cyst growth in the epidermis and dermis. Tethered spinal cord can result in gait difficulties and sphincter dysfunction, as well as compressing the spine.